Open AccessThe novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
Author(s) -
Kevin S. Quackenbush,
Stacey M. Bagby,
Wai Meng David Tai,
Wells A. Messersmith,
Anna Schreiber,
Justin Greene,
Jihye Kim,
Guoliang Wang,
Alicia Purkey,
Todd M. Pitts,
Anguyen,
Dexiang Gao,
Patrick J. Blatchford,
Anna Capasso,
Alwin G. Schuller,
S. Gail Eckhardt,
John J. Arcaroli
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.8626
Subject(s) - irinotecan , wnt signaling pathway , axin2 , colorectal cancer , cancer research , medicine , oxaliplatin , pharmacology , cancer , biology , signal transduction , microbiology and biotechnology
Dysregulation of the canonical Wnt signaling pathway has been implicated in colorectal cancer (CRC) development as well as incipient stages of malignant transformation. In this study, we investigated the antitumor effects of AZ1366 (a novel tankyrase inhibitor) as a single agent and in combination with irinotecan in our patient derived CRC explant xenograft models.